ReNeuron Group's (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company's a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron Group PLC: Proactive One2One Virtual Event
Quick facts: ReNeuron Group PLC
Price: 117 GBX
Market Cap: £37.26 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE